Latest Updates
-
Winter Care Guide: Expert Tips to Improve Your Child’s Immunity -
The Celebrity Weddings That Took Us From “I’m Engaged” to “Just Married” In 2025 -
Rs 50,700 Jump in Gold Rate in India Over 4 Days in 24K/100gm; Silver Rate Today Continues Rally on Christmas, 25 December 2025: Check Latest Prices in Chennai, Mumbai, Bangalore, Hyderabad With Gold, Silver Rate Prediction -
“67” Is Dictionary.com’s 2025 Word of the Year: The Viral Trend With No Meaning That Took Over the Internet -
Bus Catches Fire After Collision With Lorry In Karnataka; At Least 10 Dead -
Skin Cycling, Glass Skin, and Sunscreen Stacking: The Internet’s Craziest Skincare Trends Explained -
Post-Christmas Bloating Is Real: What Your Body Is Trying to Tell You -
Atal Bihari Vajpayee Birthday 2025: Celebrating Good Governance Day in India -
Think Twice This Christmas 2025: These Gifts Are A Total No For These Zodiac Signs -
Daily Horoscope, Dec 25, 2025: Libra to Pisces; Astrological Prediction for all Zodiac Signs
Actos Reduces Conversion To Type 2 Diabetes
A new study has shown that people in prediabetic state were 81 pct less likely to convert into type 2 diabetes patients when treated with drug pioglitazone, brand name Actos®.
Lead researcher Dr. Ralph A. DeFronzo, professor and chief of diabetes at The University of Texas Health Science Center at San Antonio, said the study also showed that the patients randomized to take pioglitazone also recovered part of their insulin production and their bodies became more sensitive to insulin, therefore using it more efficiently to control plasma glucose or blood sugar,
“Prediabetes, I believe, is really diabetes," said Dr. DeFronzo.
The study involved 602 individuals with impaired glucose tolerance, a prediabetic state, along with 102 healthy controls.
Pioglitazone corrects two core defects in type 2 diabetes, insulin resistance and beta cell failure. Beta cells are the cells in the pancreas that secrete insulin.
“The drug is the best insulin sensitizer we have and it also preserves beta cell function. The clinical response in this study is next to astronomical, not 100 percent but obviously highly significant."
The findings revealed that 10 subjects with impaired glucose tolerance developed diabetes while taking pioglitazone as compared to 45 subjects with impaired glucose tolerance who developed diabetes after receiving a placebo.
It also showed that 42 percent of individuals in the pioglitazone arm of the study returned to normal glucose tolerance at the study"s end versus 28 percent of those in the placebo arm.
Currently, no drug is approved by the U.S. Food and Drug Administration for treatment of prediabetes to prevent progression to diabetes.
A drug to treat impaired glucose tolerance and prevent further decline is therefore of great importance.
The
findings
were
presented
on
June
9
during
the
68th
Scientific
Sessions
of
the
American
Diabetes
Association
in
San
Francisco.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications











